And in a study on patients with GBM surviving more than 1 year, the expression of EGFR vIII was found to be an independent negative prognostic marker of survival, indicating it as a key potential target for anti-tumor immunotherapy [100]. This evidence concerns the gene EGFR and glioblastoma.